Contact
searchSearch
HMP Global
Login

CEACAM5 Biological Pathways Reviews

Videos

Sami Diab, MD
Videos
Updated NCCN Guidelines Strengthen Support for Breast Cancer Index® in Extended Endocrine Therapy Decision-Making
01/23/2026
Sami Diab, MD, discusses recent updates to the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer, which reinforces the Breast Cancer Index® as the only genomic test predictive of benefit from extended endocrine therapy in...
Sami Diab, MD, discusses recent updates to the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer, which reinforces the Breast Cancer Index® as the only genomic test predictive of benefit from extended endocrine therapy in...
Sami Diab, MD, discusses recent...
01/23/2026
Oncology
Jessica Walchonski, PA-C, MMS
Conference Coverage
Exploring Key Advances and Emerging Therapies in Gynecologic Oncology
01/23/2026
Jessica Walchonski, PA-C, MMS, reviewed recent advances in gynecologic oncology, highlighting new targeted and immunotherapy options for ovarian cancer and evolving strategies for endometrial cancer at the 2025 Oncology Learning Network APP...
Jessica Walchonski, PA-C, MMS, reviewed recent advances in gynecologic oncology, highlighting new targeted and immunotherapy options for ovarian cancer and evolving strategies for endometrial cancer at the 2025 Oncology Learning Network APP...
Jessica Walchonski, PA-C, MMS,...
01/23/2026
Oncology Learning Network APP Institute
Matthew Connor, MD
Conference Coverage
Evolving Strategies for the Treatment of Acute Lymphoblastic Leukemia
01/22/2026
Matthew Connor, MD
Matthew Connor, MD, highlighted emerging ASH 2025 data showing earlier use of CAR T-cell therapy and novel antigen targets for acute lymphoblastic leukemia, along with ponatinib-based frontline strategies.
Matthew Connor, MD, highlighted emerging ASH 2025 data showing earlier use of CAR T-cell therapy and novel antigen targets for acute lymphoblastic leukemia, along with ponatinib-based frontline strategies.
Matthew Connor, MD, highlighted...
01/22/2026
Oncology
Ira Zackon, MD
Conference Coverage
Real-World Analysis Shows Rapid Uptake of Bispecific Antibodies in Community Settings for Multiple Myeloma Treatment
01/22/2026
Ira Zackon, MD
Ira Zackon, MD, shared results which found bispecific antibody use is rapidly increasing in US community oncology practices for heavily pretreated multiple myeloma, with overall survival outcomes comparable to clinical trials.
Ira Zackon, MD, shared results which found bispecific antibody use is rapidly increasing in US community oncology practices for heavily pretreated multiple myeloma, with overall survival outcomes comparable to clinical trials.
Ira Zackon, MD, shared results...
01/22/2026
Oncology
Saad Usmani, MD, MBA, FACP, FASCO
Conference Coverage
KTX1001 Monotherapy Shows Clinical Activity and Manageable Safety for R/R Myeloma
01/22/2026
Saad Usmani, MD, MBA, FACP, FASCO
Saad Usmani, MD, MBA, FACP, FASCO, shared that the oral NSD2 inhibitor, KTX1001, showed promising clinical activity with manageable safety for relapsed/refractory multiple myeloma, including high-risk t(4;14) disease.
Saad Usmani, MD, MBA, FACP, FASCO, shared that the oral NSD2 inhibitor, KTX1001, showed promising clinical activity with manageable safety for relapsed/refractory multiple myeloma, including high-risk t(4;14) disease.
Saad Usmani, MD, MBA, FACP,...
01/22/2026
Oncology
Ola Landgren, MD, PhD
Conference Coverage
Daratumumab Plus Teclistamab Demonstrates Favorable Safety and Efficacy for Smoldering Multiple Myeloma: REVIVE Study
01/22/2026
C. Ola Landgren, MD, PhD
Ola Landgren, MD, PhD, shared early results from the phase 2 REVIVE study which showed daratumumab plus teclistamab can be safely administered for high-risk smoldering myeloma.
Ola Landgren, MD, PhD, shared early results from the phase 2 REVIVE study which showed daratumumab plus teclistamab can be safely administered for high-risk smoldering myeloma.
Ola Landgren, MD, PhD, shared...
01/22/2026
Oncology
Jeff Sharman, MD
Conference Coverage
Mosunetuzumab Demonstrates Strong Efficacy for Elderly Patients With Diffuse Large B-Cell Lymphoma
01/22/2026
Jeff P. Sharman
Jeff Sharman, MD, reported phase 2 results that showed frontline mosunetuzumab therapy produced high response rates with minimal toxicity among elderly, treatment-naive patients with DLBCL who were unfit for standard chemotherapy.
Jeff Sharman, MD, reported phase 2 results that showed frontline mosunetuzumab therapy produced high response rates with minimal toxicity among elderly, treatment-naive patients with DLBCL who were unfit for standard chemotherapy.
Jeff Sharman, MD, reported phase...
01/22/2026
Oncology
Lauren Miller, MD
Videos
Real-World Considerations for Perioperative Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma
01/21/2026
Lauren Miller, MD, discusses real-world challenges and opportunities of pembrolizumab use in patients with advanced PD-L1–positive head and neck squamous cell carcinoma.
Lauren Miller, MD, discusses real-world challenges and opportunities of pembrolizumab use in patients with advanced PD-L1–positive head and neck squamous cell carcinoma.
Lauren Miller, MD, discusses...
01/21/2026
Oncology
James Cleary, MD, PhD, Dana-Farber Cancer Institute
Videos
Treatment Sequencing in BRCA-Mutated Pancreatic Cancer
01/19/2026
James Cleary, MD, PhD
James Cleary, MD, PhD, discusses a case demonstrating how molecularly guided therapy in a patient with BRCA2-mutated metastatic pancreatic cancer led to exceptional and durable disease control with platinum-based chemotherapy followed by...
James Cleary, MD, PhD, discusses a case demonstrating how molecularly guided therapy in a patient with BRCA2-mutated metastatic pancreatic cancer led to exceptional and durable disease control with platinum-based chemotherapy followed by...
James Cleary, MD, PhD, discusses...
01/19/2026
Oncology
Scott Kopetz, MD, PhD
Conference Coverage
Encorafenib Plus Cetuximab and FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
01/16/2026
Scott Kopetz, MD, PhD
Scott Kopetz, MD, PhD, discusses results from Cohort 3 of the phase 3 BREAKWATER study evaluating encorafenib plus cetuximab with FOLFIRI versus control therapy in previously untreated BRAF V600E-mutant metastatic colorectal cancer.
Scott Kopetz, MD, PhD, discusses results from Cohort 3 of the phase 3 BREAKWATER study evaluating encorafenib plus cetuximab with FOLFIRI versus control therapy in previously untreated BRAF V600E-mutant metastatic colorectal cancer.
Scott Kopetz, MD, PhD, discusses...
01/16/2026
Oncology
OLN

CEACAM5

ALIASES

Carcinoembryonic antigen-related cell adhesion molecule 5

References

Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is a cell surface glycoprotein that is a member of the carcinoembryonic antigen family, which contains 12 glycoproteins. It is used as a clinical biomarker for many different cancers. It may promote tumor development, metastasis, and cell adhesion by inhibiting differentiation and apoptosis, while disrupting tissue architecture through its role as a cell adhesion molecule.1,2

Understanding the Role of CEACAM5

This animation explains the role of the CEACAM5 glycoprotein in the inhibition of cell differentiation and apoptosis, which can promote tumor growth and metastasis.

Expression in Cancer

Breast Cancer
50%
Colorectal Cancer
90%
Gastrointestinal Cancer
90%
Non-Small Cell Lung Cancer
70%
Pancreatic Cancer
90%
Prostate Cancer
60%

Resources

News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology
News
Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer
01/21/2026
Stephanie Holland
According to results from the phase 3 ARTS trial, adjuvant aumolertinib demonstrated strong clinical promise with a manageable safety profile among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 3 ARTS trial, adjuvant aumolertinib demonstrated strong clinical promise with a manageable safety profile among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/21/2026
Oncology
News
FDA Issues Draft Guidance on Use of MRD and Complete Response as End Points to Support Accelerated Approval in Multiple Myeloma
01/20/2026
Emily Estrada
On January 20, 2026, the FDA issued guidance outlining recommendations for the use of minimal residual disease and complete response as primary end points to support accelerated approval of drugs and biologics for the treatment of multiple...
On January 20, 2026, the FDA issued guidance outlining recommendations for the use of minimal residual disease and complete response as primary end points to support accelerated approval of drugs and biologics for the treatment of multiple...
On January 20, 2026, the FDA...
01/20/2026
Oncology
News
Adding Atezolizumab to Chemoradiation Fails to Improve Outcomes for Limited-Stage SCLC
01/19/2026
Gina Tomaine
The addition of concurrent and adjuvant atezolizumab to standard chemoradiation did not improve survival outcomes for patients with limited-stage SCLC, according to results from the phase 3 NRG Oncology/Alliance LU005 trial.
The addition of concurrent and adjuvant atezolizumab to standard chemoradiation did not improve survival outcomes for patients with limited-stage SCLC, according to results from the phase 3 NRG Oncology/Alliance LU005 trial.
The addition of concurrent and...
01/19/2026
Oncology
News
Berzosertib Plus Topotecan for Patients With Relapsed Platinum-Resistant Small-Cell Lung Cancer: DDRiver SCLC 250 Study
01/15/2026
Gina Tomaine
Berzosertib plus topotecan did not yield meaningful clinical benefits for patients with relapsed, platinum-resistant SCLC compared with topotecan monotherapy, according to phase 2 study results.
Berzosertib plus topotecan did not yield meaningful clinical benefits for patients with relapsed, platinum-resistant SCLC compared with topotecan monotherapy, according to phase 2 study results.
Berzosertib plus topotecan did...
01/15/2026
Oncology
News
Prophylactic Tocilizumab May Limit Tarlatamab Toxicities for High-Risk Patients With Extensive-Stage Small Cell and Neuroendocrine Lung Cancer
01/15/2026
Gina Tomaine
Tarlatamab for patients with ES-SCLC and neuroendocrine lung cancer was associated with higher CRS and ICANS rates in real-world settings than in trials, while prophylactic tocilizumab may mitigate these toxicities, according to a...
Tarlatamab for patients with ES-SCLC and neuroendocrine lung cancer was associated with higher CRS and ICANS rates in real-world settings than in trials, while prophylactic tocilizumab may mitigate these toxicities, according to a...
Tarlatamab for patients with...
01/15/2026
Oncology
News
Oral Iberdomide Combination Demonstrates Clinically Meaningful Activity for R/R Multiple Myeloma
01/14/2026
Emily Estrada
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of...
01/14/2026
Oncology
News
High Non-Relapse Mortality Remains Barrier to Allogeneic Transplantation Success Rates for Patients With Myelofibrosis
01/14/2026
Emily Estrada
Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.
Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.
Among patients with...
01/14/2026
Oncology
News
Pacritinib Therapy Shows Improved Symptom Reduction and Spleen Response for Patients With Myelofibrosis and Thrombocytopenia
01/14/2026
Emily Estrada
Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...
Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...
Pacritinib therapy showed...
01/14/2026
Oncology

Podcasts

Podcasts
Treatment of Recurrent Refractory Pediatric Low-Grade Glioma (pLGG)
01/02/2026
Cassie Kline, MD, MAS
Dr Cassie Klein presents a three-year update from the phase 2 FIREFLY-1 trial evaluating tovorafenib, a weekly oral type II RAF inhibitor, in recurrent or refractory pediatric low-grade glioma. She emphasizes the importance of incorporating...
Dr Cassie Klein presents a three-year update from the phase 2 FIREFLY-1 trial evaluating tovorafenib, a weekly oral type II RAF inhibitor, in recurrent or refractory pediatric low-grade glioma. She emphasizes the importance of incorporating...
Dr Cassie Klein presents a...
01/02/2026
Oncology
Podcasts
Case Files: Axatilimab Use in a Patient With Chronic Graft-Versus-Host-Disease 
09/16/2025
Benjamin Watkins, MD
A case-based discussion on using axatilimab, including toxicity experience. 
A case-based discussion on using axatilimab, including toxicity experience. 
A case-based discussion on using...
09/16/2025
Oncology
Podcasts
Navigating Second-Line Decisions: Real-World Management of Chronic Graft-Versus-Host Disease (GVHD)
09/16/2025
Shernan Holtan, MD
This podcast highlights results from a recent trial on the long-term effects of ruxolitinib in transplant patients with graft-versus-host disease. 
This podcast highlights results from a recent trial on the long-term effects of ruxolitinib in transplant patients with graft-versus-host disease. 
This podcast highlights results...
09/16/2025
Oncology
Podcasts
From Steroids to Second-Line Therapy—What Drives the Move? 
09/16/2025
Betty Hamilton, MD
An engaging discussion on what drives the move from steroids to a second-line or subsequent third-line therapy for chronic graft-versus-host disease? Are they really the definitions we see in trials, or are they different?
An engaging discussion on what drives the move from steroids to a second-line or subsequent third-line therapy for chronic graft-versus-host disease? Are they really the definitions we see in trials, or are they different?
An engaging discussion on what...
09/16/2025
Oncology
Podcasts
Beyond Symptoms: Navigating Chronic Graft-Versus-Host Disease Assessment 
09/16/2025
Yi-Bin Chen, MD
"Beyond Symptoms: Navigating Chronic Graft-Versus-Host Disease Assessment," which covers the symptomatic nature of cGVHD and provides quick tips for adequately assessing chronic graft-versus-host disease symptoms. 
"Beyond Symptoms: Navigating Chronic Graft-Versus-Host Disease Assessment," which covers the symptomatic nature of cGVHD and provides quick tips for adequately assessing chronic graft-versus-host disease symptoms. 
"Beyond Symptoms: Navigating...
09/16/2025
Oncology
Podcasts
Podcast: Selecting Second-Line Therapy for Relapsing/Remitting Pediatric Low-Grade Glioma (pLGG)
05/13/2025
Dr Eugene Hwang explores the evolving role of targeted therapies in recurrent pediatric low-grade glioma (pLGG)—balancing molecular precision, quality of life, and real-world treatment logistics in the quest for optimal care.
Dr Eugene Hwang explores the evolving role of targeted therapies in recurrent pediatric low-grade glioma (pLGG)—balancing molecular precision, quality of life, and real-world treatment logistics in the quest for optimal care.
Dr Eugene Hwang explores the...
05/13/2025
Oncology
Podcasts
Podcast: Targeted Therapies for Relapsing/Remitting Pediatric Low-Grade Glioma (R/R pLGG)
05/13/2025
Dr Eugene Hwang delves into the evolving landscape of MEK and BRAF inhibitors for pediatric low-grade glioma (pLGG), comparing efficacy, side effects, and next-gen strategies shaping frontline and salvage care.
Dr Eugene Hwang delves into the evolving landscape of MEK and BRAF inhibitors for pediatric low-grade glioma (pLGG), comparing efficacy, side effects, and next-gen strategies shaping frontline and salvage care.
Dr Eugene Hwang delves into the...
05/13/2025
Oncology
Dr Hwang
Podcasts
Podcast: Oncogenic Drivers of Pediatric Low-Grade Glioma (pLGG)
05/13/2025
Dr Eugene Hwang unpacks the molecular underpinnings of pediatric low-grade glioma (pLGG)—highlighting how MAPK pathway alterations are reshaping diagnosis, prognosis, and the promise of precision therapies.
Dr Eugene Hwang unpacks the molecular underpinnings of pediatric low-grade glioma (pLGG)—highlighting how MAPK pathway alterations are reshaping diagnosis, prognosis, and the promise of precision therapies.
Dr Eugene Hwang unpacks the...
05/13/2025
Oncology
Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
Podcasts
Sacituzumab Govitecan Plus Pembrolizumab in the TROPHY-U-01 Trial
03/07/2024

Featured Petros Grivas, MD, PhD

Featured Petros Grivas, MD, PhD ...
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares...
03/07/2024
Oncology
Sara Hurvitz, MD, David Geffen School of Medicine – UCLA, Los Angeles, CA
Podcasts
Neoadjuvant Chemotherapy Plus HER2-Targeted Therapy for Early Stage HER2-Positive Breast Cancer
02/16/2023
Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.
Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.
Sara Hurvitz, MD, shares how she...
02/16/2023
Oncology

Interactive

Quiz
Rovadicitinib for Ruxolitinib-Resistant or Intolerant Myelofibrosis
01/14/2026
True or False: The first-in-class oral JAK/ROCK inhibitor, rovadicitinib, did not demonstrate promising clinical responses or a favorable safety profile among patients with myelofibrosis who were relapsed/refractory or intolerant to prior...
True or False: The first-in-class oral JAK/ROCK inhibitor, rovadicitinib, did not demonstrate promising clinical responses or a favorable safety profile among patients with myelofibrosis who were relapsed/refractory or intolerant to prior...
True or False: The...
01/14/2026
Oncology
Quiz
CMS4 and Anti-EGFR Benefit in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/13/2026
True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...
True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...
True or False: Consensus...
01/13/2026
Oncology
Quiz
Eflornithine Plus Lomustine for Recurrent Grade 3 Astrocytoma
01/13/2026
True or false: Eflornithine combined with lomustine significantly prolonged both progression-free and overall survival in patients with recurrent IDH-mutant, grade 3 astrocytoma following prior radiotherapy and temozolomide, compared with...
True or false: Eflornithine combined with lomustine significantly prolonged both progression-free and overall survival in patients with recurrent IDH-mutant, grade 3 astrocytoma following prior radiotherapy and temozolomide, compared with...
True or false: Eflornithine...
01/13/2026
Oncology
Quiz
Chidamide Plus Azacitidine Maintenance Therapy for AML
01/12/2026
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following...
01/12/2026
Oncology
Quiz
Treatment of Recurrent Refractory Pediatric Low-Grade Glioma (pLGG): Pre-Content Quiz
01/02/2026
01/02/2026
Oncology
Quiz
Molecular Drivers of Pigmented Villonodular Synovitis
12/18/2025
Which of the following molecular features were found to be most strongly associated with disease progression in pigmented villonodular synovitis?
Which of the following molecular features were found to be most strongly associated with disease progression in pigmented villonodular synovitis?
Which of the following molecular...
12/18/2025
Oncology
Quiz
Evaluating Pembrolizumab Plus Chemotherapy in Extensive SCLC
12/17/2025
The phase 2 REACTION trial aimed to assess the addition of pembrolizumab to first-line platinum-etoposide in chemo-sensitive patients with extensive-stage small cell lung cancer. Which of the following best summarizes the efficacy findings?
The phase 2 REACTION trial aimed to assess the addition of pembrolizumab to first-line platinum-etoposide in chemo-sensitive patients with extensive-stage small cell lung cancer. Which of the following best summarizes the efficacy findings?
The phase 2 REACTION trial aimed...
12/17/2025
Oncology
Quiz
Early Switch to Camizestrant at ESR1 Mutation Emergence in HR-Positive, HER2-Negative Advanced Breast Cancer
12/12/2025
The phase 3 SERENA-6 trial evaluated an early switch to camizestrant plus continued CDK4/6 inhibition at the time of ESR1 mutation emergence in patients with HR-positive, HER2-negative advanced breast cancer.Which of the following best...
The phase 3 SERENA-6 trial evaluated an early switch to camizestrant plus continued CDK4/6 inhibition at the time of ESR1 mutation emergence in patients with HR-positive, HER2-negative advanced breast cancer.Which of the following best...
The phase 3 SERENA-6 trial...
12/12/2025
Oncology
Quiz
Niraparib Plus Dostarlimab for Patients With Germline BRCA1/2-Mutated TNBC
12/11/2025
According to the phase 2 TBCRC 056 trial of neoadjuvant niraparib plus dostarlimab in patients with germline BRCA1/2-mutated triple-negative breast cancer, which of the following best describes the observed antitumor and immunologic activity?
According to the phase 2 TBCRC 056 trial of neoadjuvant niraparib plus dostarlimab in patients with germline BRCA1/2-mutated triple-negative breast cancer, which of the following best describes the observed antitumor and immunologic activity?
According to the phase 2 TBCRC...
12/11/2025
Oncology
Quiz
FDA Approves Tarlatamab for Extensive-Stage Small Cell Lung Cancer
12/10/2025
Which of the following statements best reflects the efficacy outcomes that supported conversion of tarlatamab’s accelerated approval to traditional approval for previously treated ES-SCLC in the phase 3 DeLLphi-304 trial?
Which of the following statements best reflects the efficacy outcomes that supported conversion of tarlatamab’s accelerated approval to traditional approval for previously treated ES-SCLC in the phase 3 DeLLphi-304 trial?
Which of the following...
12/10/2025
Oncology

Anti-CEACAM5 Antibodies

Therapies targeting CEACAM5 are currently in development for the treatment of multiple cancer types. This table outlines therapies in the pipeline.

Table icon
View Table
X

Anti-CEACAM5 Antibodies in the Pipeline

Generic Drug Name

Potential Indications

Tusamitamab ravtansine1-3

An antibody-drug conjugate targeting CEACAM5 being evaluated for the treatment of patients with non-small cell lung cancer, metastatic breast cancer, and metastatic pancreatic adenocarcinoma.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use